1. Home
  2. SCLX vs CRT Comparison

SCLX vs CRT Comparison

Compare SCLX & CRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • CRT
  • Stock Information
  • Founded
  • SCLX 2011
  • CRT 1991
  • Country
  • SCLX United States
  • CRT United States
  • Employees
  • SCLX N/A
  • CRT N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • CRT Oil & Gas Production
  • Sector
  • SCLX Health Care
  • CRT Energy
  • Exchange
  • SCLX Nasdaq
  • CRT Nasdaq
  • Market Cap
  • SCLX 35.7M
  • CRT 42.5M
  • IPO Year
  • SCLX N/A
  • CRT 1992
  • Fundamental
  • Price
  • SCLX $16.46
  • CRT $7.87
  • Analyst Decision
  • SCLX Buy
  • CRT
  • Analyst Count
  • SCLX 2
  • CRT 0
  • Target Price
  • SCLX $245.00
  • CRT N/A
  • AVG Volume (30 Days)
  • SCLX 255.7K
  • CRT 29.3K
  • Earning Date
  • SCLX 08-13-2025
  • CRT 01-01-0001
  • Dividend Yield
  • SCLX N/A
  • CRT 9.42%
  • EPS Growth
  • SCLX N/A
  • CRT N/A
  • EPS
  • SCLX N/A
  • CRT 0.92
  • Revenue
  • SCLX $44,236,000.00
  • CRT $6,559,820.00
  • Revenue This Year
  • SCLX $89.26
  • CRT N/A
  • Revenue Next Year
  • SCLX $203.95
  • CRT N/A
  • P/E Ratio
  • SCLX N/A
  • CRT $8.56
  • Revenue Growth
  • SCLX N/A
  • CRT N/A
  • 52 Week Low
  • SCLX $3.60
  • CRT $7.07
  • 52 Week High
  • SCLX $39.90
  • CRT $13.31
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 47.62
  • CRT 58.49
  • Support Level
  • SCLX $13.08
  • CRT $7.07
  • Resistance Level
  • SCLX $14.74
  • CRT $7.72
  • Average True Range (ATR)
  • SCLX 1.51
  • CRT 0.20
  • MACD
  • SCLX -0.07
  • CRT 0.07
  • Stochastic Oscillator
  • SCLX 55.24
  • CRT 84.53

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About CRT Cross Timbers Royalty Trust

Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.

Share on Social Networks: